DRKS00030915招募中4 期
Single-case prediction of treatment (non-) response to cognitive-behavioral therapy (CBT) in the outpatient sector: a prospective-longitudinal observational study - TiKi-Study
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 585
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Inclusion criteria are: a primary diagnosis according to DSM-5 of specific phobia (SP), social anxiety disorder (SAD), panic disorder (PD), agoraphobia (AG), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), unipolar depressive disorder (major depression or dysthymia, DD), age = 18, indication for outpatient CBT treatment, treatment dose of at least 12 sessions (excluding probatory sessions; 12 sessions is a minimal fixed dose of short-term treatment in the German health care system), symptom severity as indicated by a General Severity Index of the Brief Symptom Inventory (BSI-GSI) > 0.56 and a Clinical Global Impression – Severity Scale (CGI-S) score = 3 (mildly ill), willingness to participate in this study. Fostering ecological validity, exclusion criteria will be kept to a minimum.
排除标准
- •We will exclude patients with a current secondary diagnosis of moderate to severe substance use disorder (including regular use of benzodiazepines), psychosis, bipolar disorder, acute suicidality and medical conditions as contraindication for CBT. Other comorbid disorders from the internalizing spectrum are not excluded. If outpatient treatment is interrupted due to inpatient treatment, patients will be excluded. Concurrent pharmacological treatment is not followed by exclusion, but will be documented in detail.
研究者
相似试验
已完成
不适用
Prediction of outcomes and response to treatments with an ultrasensitive method for assessing intratumor epigenetic heterogeneity in colorectal cancerColorectal cancerJPRN-UMIN000021191Juntendo University Faculty of Medicine60
招募中
不适用
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosisDRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600
已完成
不适用
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).Rheumatoid arthritisJPRN-UMIN000020134Jichi Medical University56
招募中
不适用
Validation of a Single-Subject Treatment Outcome Predictor for Repetitive Transcranial Magnetic Stimulation (rTMS) to Improve Negative Symptoms in SchizophreniaDSM-5: Schizophrenia spectrum and other psychotic disordersF20SchizophreniaDRKS00022214Klinikum der Universität München, Campus Großhadern76
已完成
不适用
Observational study on clinical outcome prediction of anti-epidermal growth factor receptor for colorectal cancer based on DNA methylation status and gene expression status.Metastatic colorectal cancerJPRN-UMIN000027296Institute of Development, Aging and Cancer (IDAC), Tohoku University159